Moderna (MRNA) Stock Plunges Over 10% Amid Insider Sales and Bearish Analyst Outlook
Moderna (MRNA) dropped 10.7% to $68.39 on July 10. Insiders dumped $6.2M, earnings fell short, and analysts maintain 'Reduce' ratings. The post Moderna (MRNA) Stock Plunges Over 10% Amid Insider…
Read the full articleYou might also wanna read
Short Squeeze Alert—Moderna Stock Surges on New Strategy
Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-ye
Moderna Stock Drops After Morgan Stanley Sticks To Neutral Rating Despite Lifting Price Target
Moderna stock fell 7% despite Morgan Stanley raising its price target to $39, as the firm kept its neutral rating in place.
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives?
When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.
Moderna Stock Is Soaring. Is It Too Late to Buy?
Moderna's growth story is just beginning.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors
Moderna: mRNA-Pipeline für Atemwegserkrankungen stärkt die Aktie
CAMBRIDGE / LONDON (IT BOLTWISE) – Moderna bleibt für viele Anleger ein Aktiencase, der deutlich an der Entwicklung der mRNA-Plattform und d
Comments
Sign in to join the conversation.
No comments yet. Be the first.